Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2023-03 · 57 (6) · 666-675
DOI: 10.1111/apt.17379 ↗At a glance
Systematische Übersicht in Alimentary Pharmacology & Therapeutics, published online on 2022-12-31. Written by Shahida Din and 3 co-authors. Institution: Edinburgh Inflammatory Bowel Diseases Unit, Western General Hospital, Edinburgh, UK. Major MEDLINE topics: Crohn Disease, Herpes Zoster, Inflammatory Bowel Diseases, Janus Kinase Inhibitors. Cited 84 times so far (Crossref); 64 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Biologics and small molecules for inflammatory bowel disease (IBD) may increase infection risk. Herpes zoster causes acute and long‐term symptoms, but vaccination is not recommended in patients with IBD, unless >50 years of age.
Aims
To examine risk of Herpes zoster infection with all licensed biologics and small molecules for IBD using network meta‐analysis.
Methods
We searched the literature to 4th October 2022, for randomised controlled trials of these drugs in luminal Crohn's disease or ulcerative colitis reporting data on occurrence of Herpes zoster infection during follow‐up. We used a frequentist approach and a random effects model, pooling data as relative risks (RRs) with 95% confidence intervals (CIs).
Results
We identified 25 trials (9935 patients). Only tofacitinib 10 mg b.d. (RR = 6.90; 95% CI 1.56–30.63, number needed to harm (NNH) = 97; 95% CI 19–1022) and upadacitinib 45 mg o.d. (RR = 7.89; 95% CI 1.04–59.59, NNH = 83; 95% CI 10–14,305) were significantly more likely to increase risk of Herpes zoster infection. Janus kinase inhibitors were the most likely drug class to increase risk of infection, and risk increased with higher doses (RR with lowest dose = 3.16; 95% CI 1.02–9.84, NNH = 265; 95% CI 65–28,610, RR with higher dose = 5.91; 95% CI 2.21–15.82, NNH = 117; 95% CI 39–473).
Conclusions
In a network meta‐analysis, the janus kinase inhibitor tofacitinib, and all janus kinase inhibitors considered as a class, were most likely to increase risk of Herpes zoster infection. Risk increased with higher doses.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Edinburgh Inflammatory Bowel Diseases Unit, Western General Hospital, Edinburgh, UK.
- Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
- Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
ORCID profiles: Christopher J Black, Alexander C Ford
Cite
APA
Din, S., Selinger, C. P., Black, C. J., & Ford, A. C. (2023). Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 57(6), 666-675. https://doi.org/10.1111/apt.17379
Vancouver
Din S, Selinger CP, Black CJ, Ford AC. Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2023;57(6):666-675. doi:10.1111/apt.17379
BibTeX
@article{Din2023,
author = {Din, Shahida and Selinger, Christian P and Black, Christopher J and Ford, Alexander C},
title = {Systematic review with network meta‐analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
volume = {57},
number = {6},
pages = {666--675},
doi = {10.1111/apt.17379}
}
EUVIMED